Albertans across the province can join the movement on Giving Tuesday and throughout the holiday season by visiting AlbertaCancer.ca/MoreTime to give the gift of time. Thanks to the generosity of ...
The Company recently announced that it would advance development of TZLS-501, a dual-action IL-6R monoclonal antibody targeting both membrane-bound and soluble forms of IL-6R. This decision was based ...
Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein ( GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased ...
Comanche Biopharma today announced the strengthening of its leadership team with the appointments of Richard Colvin, MD, PhD, as Global Head of Research and Development (R&D), and John McHutchison, AO ...
Christie Jones, market leader for Bandera Healthcare LLC, Ensign’s Arizona-based subsidiary, added, “We are excited to work together with the outstanding care team at the facility and combine their ...
Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regulatory approval. The foundation for her expert drug development perspectives ...
Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the ...
Additionally, pharmacokinetic analyses demonstrated no reduction in cisplatin exposure, and there was no evidence of adverse interaction or attenuation of antitumor activity. The overall tumor ...
Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with ...
In another transaction on the same day, Ensign announced that it acquired the operations of “ Santa Rosa Care Center”, a 144-bed skilled nursing facility located in Tucson, Arizona. The facility is ...
VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) is pleased to provide a corporate update following its recently released Q3 ...
Tacalyx, a privately held biotech company focused on developing novel TACA (Tumour Associated Carbohydrate Antigens) cancer therapies, announces the appointment of Jean Engela as Chief Executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback